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1. Introduction 
The renin-angiotensin system (RAS) participates in numerous biological activities. Among 
these is the pathophysiological mechanisms of hypertension, congestive heart failure, 
myocardial infarction, diabetic nephropathy and inflammatory disorders. These pleiotropic 
effects led to the development of new therapeutic approaches to inhibit the actions of this 
system. This chapter aims to relate the inflammatory process with the RAS thus focusing on 
the effects of antihypertensive drugs in the therapeutic and / or prevention of 
pathophysiological conditions. Also discussed in this chapter also the pharmacodynamic of 
ACE inhibitors, ARB inhibitors and Direct Renin Inhibitors, as well as a review of the RAS. 
For a better knowledge of the system, it is necessary to first discuss the history of RAS 
components and focusing on general biochemistry, cell biology in its overall effects. 
2. Renin-angiotensin system 
The RAS is classically known as a circulatory system or hormone that regulates blood 
pressure and homeostasis of electrolytes and fluids. This classic study is originated from 
1898 when Tiergersted and Bergman found that the kidney contained a pressor substance, 
through non-purified salt extracts, which was called renin. This discovery came only to 
attract attention with Goldblatt et al in the twentieth century in 1934 when they 
demonstrated that the constriction of the renal arteries producing persistent hypertension in 
dogs due to reduction in vascular area with a consequent increase in strength and blood 
pressure (Goldman and Gilman, 2007). Six years later he declared that the renin was actually 
a protein that acted on a substrate in plasma. The name of this substrate for 20 years was 
controversial, as two groups of researchers, one from Argentina and other U.S. called them 
differently. The first group was called the substrate of hipertensin and the second angiotonin 
until these names were changed to angiotensin, the true pressor material. The precursor of 
this peptide was called angiotensinogen. Therefore, the time had an idea this simplified 
system, Figure 1. 
In the 50's has been identified two forms of angiotensin, respectively called of angiotensin I 
and II. The first would be a chain of 10 peptides, hence the term decapeptide. In contrast, the 
second would be formed by cleavage of two peptides of angiotensin I to form an 
octapeptide. This cleavage occurs through the participation of an enzyme located on the 
luminal surface of endothelial cells of vascular system known as Angiotensin Converting 
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Enzyme (ACE). In the overview of the peptide angiotensin II is more active, that is, 
angiotensin II that has the main vasoconstrictor effect. Thus by mid-50, the overall picture of 
this system was extended by both the description of the two angiotensins, and by the 
observation that this system RAS concurrently regulated secretion of aldosterone. Based on 
this knowledge that was acquired, the 70 and 80 was an improvement on the findings of 
these polypeptides that interfere with components of the RAS, is directly inhibiting the 
release of renin, or ACE, and angiotensin receptor antagonists. Anyway, these findings 
allow to the present day an increase in quality of life, these compounds being the main drug 
involved in the treatment of hypertension, congestive heart failure, diabetic nephropathy, 
myocardial infarction, more recent studies show the effects of these in inflammatory 
disorders. To understand this ‘fine’ relationship between RAS and inflammatory process, it 
is to reading the components of this system. 
 
Fig. 1. Diagram showing the evolution in a simplified manner on the physiology of RAS. 
[Figure made by Barros, RS - 2011]. 
3. Renin angiotensin system components 
Renin: It is the major protease able of determining the rate of production of angiotensin II. 
Renin is produced, stored and secreted in so-called juxtaglomerular cells, cells that are 
circulating in the renal artery, present in the afferent arterioles, ie, the infiltrating glomerulus 
in promoting renal perfusion in this region. The release of renin is done through a process 
called as exocytosis. The main substrate of this aspartyl protease is an ǂ2 - globulin stock, ie, 
angiotensinogen that is secreted by hepatocytes. Regardless, the renin, which cleaves 
peptide bonds aminoterminal tail of the angiotensinogen (Leucyl-leucine in mice and rats) 
and (Leucine-valine in humans), leading to angiotensin I, is an active renin. Thus the 
synthesis of this protease is done in stages. The active form that contains 340 amino acids. It 
is synthesized as a pre-pro-enzyme with 406 amino acid residues, soon after, this precursor 
is processed and thus generates a pro-renin, which is a more mature, but no activity. Soon 
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after this process pro-renin is activated by an enzyme not yet characterized, but cleaves 43 
amino acids of the aminoterminal tail, thereby generating active renin. The secretion of renin 
by the juxtaglomerular cells (CJG) is controlled mainly by three ways: two act locally in the 
kidney and third acts indirectly through the CNS that releases norepinephrine from 
noradrenergic nerves of the kidney. The macula densa is a mechanism that controls the 
release of renin. It is a complex mechanism that relies on receptors, cyclic adenosine 
monophosphate (cAMP) and also through prostaglandins. In general, the macula densa is 
located adjacent to the CJG and is composed of columnar epithelial cells. When any change 
occurs in the flow of NaCl present in the macula densa cells release chemical signals that the 
CJG will inhibit or stimulate renin in the event of an increase or reduction of NaCl 
respectively. These signals via macula is mediated by both adenosine and prostaglandin by 
the first of which operates in the increase of NaCl and the second reduction. Regardless of 
which protein will act (adenosine or prostaglandin), the fact is that the answer to these is 
through the binding of these G protein coupled receptors, which will promote a signal 
dependent on the cellular second messenger (cAMP). Thus while acting within the A1 
adenosine receptor adenosine inhibits renin release, while the prostaglandin stimulates. 
The second mechanism that controls the release of renin is  intrarenal baroreceptor pathway. 
This mechanism is regulated by raising and lowering blood pressure in pre-glomerular 
vessels, and thus are regulated by mechanical phenomenon. This mechanical modulation 
causes CJG inhibit or stimulate the release of renin. Moreover, the increase or reduction in 
renal perfusion pressure may inhibit the release or renal prostaglandin which act in part via 
the intrarenal baroreceptor. 
Finally, the third mechanism is called via the beta-adrenergic receptors. In this case, 
regulation occurs via the CNS. After the release and action of this neurotransmitter 
norepinephrine from postganglionic sympathetic nerves occurs when it binds to beta-
adrenergic receptors stimulating the sympathetic pathway and consequently the secretion of 
renin by CJG. 
These three mechanisms of regulation of renin secretion are involved in a physiological 
network, explained below: 
1. The increased release of renin leads to increased release of angiotensin II. This in turn 
binds to AT1 receptors in the CJG. This binding leads to inhibition of renin secretion in 
a mechanism known as short feedback loop. 
2. In addition to angiotensin II also leads to an increase in blood pressure by binding these 
AT1 receptors. In increased pressure leads to a reduction in renin secretion through the 
action of high pressure baroreceptors, increased pressure from pre-glomerular vessels 
and reduced pressure natriuresis (drop in reabsorption of NaCl). This mechanism of 
reduction of renin secretion via increased blood pressure arising from the effects of 
angiotensin II is known as negative feedback loop long. 
Angiotensionogen: It is important to a globular protein, has a (MW = 55,000 to 60,000) and 
is the main substrate of renin. The angiotensinogen is synthesized in the liver, although it 
may have also made their transcription in adipose tissue in the CNS and kidney. There is a 
very close relationship between the synthesis and secretion of angiotensinogen by stimuli 
such as inflammation, insulin, estrogens, glucocorticoids, thyroid hormone and angiotensin 
II, ie, all these stimuli increase the synthesis and secretion of dodecahydrate peptide. There 
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is a strong relationship between the amount of circulating angiotensinogen in plasma and 
increased blood pressure, so the use of oral contraceptives containing estrogen lead to an 
increase in serum angiotensinogen, thereby resulting in an elevation of blood pressure. At 
this point becomes more clear also the strong relationship with the inflammatory process. 
We have seen that directly interferes with the prostaglandin release of renin, ie, 
prostaglandins increase the secretion of this hormone by binding to adenosine receptors. 
Angiotensin Converting Enzyme (ACE): ACE is a glycoprotein ecto-enzyme and that in 
addition to cleaving angiotensin I to angiotensin II forming this ecto-enzyme can also 
inactivate bradykinin, because ACE is very nonspecific and can cleave dipeptide units with 
many amino acid substrate. Therefore, the ACE inhibitors such as captopril and lisinopril, 
for example, are able to increase bradykinin and reduce angiotensin II. The rapid in vivo 
conversion of angiotensin I to II occurs through the action of ACE that is present on the 
luminal surface of endothelial cells throughout the vascular system. In addition to these 
effects of ACE some studies show the existence of a carboxypeptidase-related enzyme called 
ACE2 is capable of cleaving angiotensin I into (angiotensin 1-9) and angiotensin II 
(angiotensin 1-7). This enzyme is not inhibited by classic ACE inhibitors. Its physiological 
importance is not yet clear. 
4. The renin-angiotensin system and its relationship with pathophisiology 
hypertension 
The pathophysiology of hypertension is defined as a lasting elevation of blood pressure to ≥ 
140/90 mmHg, as this procedure was used because most individuals with this pressure 
range belong to risk group cardiovascular disease and hypertension arising from the 
medical attention they deserve. This disease is like the most common cardiovascular disease 
and its prevalence increases with age. 
The RAS participates as a key player in regulating blood pressure in both long and short 
term. This happens because the increase, even in modest concentrations of angiotensin II 
leads to an acute elevation of blood pressure. To get an idea in terms of values to 
angiotensin II is about 40 times more potent than norepinephrine and effective 
concentration (EC50) to angiotensin II acute elevation of blood pressure is approximately 0.3 
nmol / l. In the presence of angiotensin II administered intravenously pressure rises in a few 
seconds and after a few minutes this reduces the normal rate. This effect is known as 
immediate pressor response is due to a rapid increase in total peripheral resistance. This 
increased resistance is a response that maintains blood pressure in the presence of an acute 
hypotensive response. Although the direct effects of angiotensin II on cardiac contractility 
and heart rate indirect in the rapid rise in blood pressure leads to activation of the 
baroreceptor reflex, and in a negative feedback, this occurs with the reduction of 
sympathetic tone and increase vagal tone. 
On the other hand, there is a slow pressor response, which also occurs by the action of 
angiotensin II. Response to this pressure is stabilized for a long time. This slow pressor 
response is most likely due to reduced renal excretion function, causing an increase in fluid 
retention and salt and, with increasing pressure quently. Associated with these renal effects, 
angiotensin II in this response also induces the synthesis of endothelin-1 and superoxide 
anion, which can contribute to this type of slow pressor response. Other classical effects of 
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angiotensin II on the pathophysiology of hypertension is the morphological alteration of the 
cardiovascular system, causing hypertrophy of cardiac and vascular cells, and increase the 
synthesis and deposition of collagen by cardiac fibroblasts.  
5. Antihypertensive drugs and its relationship to inflammation 
As discussed previously classicaly, the rennin-angiotensin system (RAS) has been 
considered a hormonal circulating system. The so-called systemic or circulating RAS plays a 
crucial role in the maintenance of blood pressure and electrolyte as well as fuid 
homeostasis15. This is mediated through its constrictive actions on vascular smooth muscle 
and by its influence on aldosterone secretion from the adrenal cortex, electrolyte transport in 
kidney, and on thirst as well as sodium appetite in the brain. In addition to its actions on the 
cardiovascular, renal, and nervous system, the expression of local RAS components in 
tissues such as the brain, kidneys, adrenals and gonads has led to the proposition that these 
components may either potentate systemic functions, or have entirely separate activities 
meeting the specific needs of these individual tissues.There is accumulating evidence that 
changes in tissue/organ-specific RAS may be associated with the pathophysiology of the 
respective tissue/organ functions (Ip et al., 2003). 
The final goal of the RAS is the angiotensin II production that acts through the interaction 
with two pharmacologically defined receptor subtypes, namely type 1 (At1) and type 2 (At2) 
that are distributed in numerous target tissues and organs like pancreas, for example (Chan 
et al., 2000). 
Some studies show that AT1 and AT2 receptors when activated by angiotensin II may lead 
to tissue that expresses inflammatory responses develop. This is the case of acute 
pancreatitis, which expresses the receptor AT1a more significantly than the receiver AT1b. 
In contrast, the AT2 receptor is most often responsible for these inflammatory responses 
more pronounced. 
The role of RAS in the inflammatory process was further evidenced by the ability of an ACE 
inhibitor to suppress inflammation and subsequent tissue injury (Pupilli et al., 1999). Some 
studies suggest that losartan, an At1 blocker, and lisinopril, an angiotensin-converting 
enzyme (ACE) inhibitor, can inhibit both the liver fibrosis and portal hypertension occurring 
in secondary biliary cirrhosis by inhibiting hepatic stellate cells (HSCs) activation (Agarwal 
et al.,1993). Other studies in vitro of cultured pancreatic stellate cells have demonstrated that 
these cells exhibit morphological and functional features similar to cultured hepatic stellate 
cells, including positive SMA staining after a period of time in culture, increased 
proliferation in response to PDGF, and increased collagen synthesis in response to TGF-ǃ 
(Gressner et al., 1995). So these stellate cells could trigger an inflammatory process in the 
tissue which is expressed. 
Although other tissues, these stellate cells can not express the AT1 and AT2 receptors are 
widely distributed throughout the system and this can lead to a local inflammatory response 
by angiotensin II signaling. Given this relationship, it is necessary to comment briefly on the 
mechanism of action of antihypertensive agents shown below. 
ACE Inhibitors: The essential effect of the agents belonging to this group of drugs is just the 
inhibition of the conversion of angiotensin I to II. In this respect ACE inhibitors are selective 
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drugs, but because ACE has multiple substrates, these inhibitors may induce effects not 
related to reduced synthesis of angiotensin II. Among these various effects is the increased 
synthesis of bradykinin and prostaglandins that may contribute to the effects of ACE 
pharmacological inhibitors. A study by Silva, RB et al. (2010) in the Faculty of Medicine of 
Ribeirão Preto - FMRP / USP, Sao Paulo - Brazil, demonstrated that the application of drugs 
such as Lisinopril significantly reduced inflammatory response in an experimental model of 
acute pancreatitis, illustrating the relationship between the RAS and inflammation , figure 2. 
    
A   B 
Fig. 2. Map showing histopathological in (A) - The severe inflammatory process in the 
experimental group of acute pancreatitis and (B) - A significant reduction in inflammation in 
animals treated with lisinopril (Silva, R et al, 2010). 
Captopril: Captopril was the first ACE inhibitor to be marketed. This drug has a 
bioavailability of about 75% and undergoes rapid absorption. Most of this drug is excreted 
in the urine, about 40 to 50% in the form of captopril and the remainder in the form of 
dimers. Captopril contains a sulfhydryl group. 
Enalapril: enalapril is a pro-drug hydrolyzed by esterases in the liver. After this hydrolysis, 
enalapril is converted into a dicarboxylic acid which is known as enalaprilat a highly potent 
inhibitor of ACE. 
Lisinopril: This drug differently than enalapril, it is active. In vitro studies show that 
Lisinopril is an ACE inhibitor slightly more potent than enalaprilat. Our study showed that 
this drug also has significant anti-inflammatory effects, but these results we have shown this 
relationship only in a specific experimental model of acute pancreatitis, requiring a slightly 
larger study, to ascertain whether this behavior also occurs in human beings. Lisinopril does 
not accumulate in the tissues. 
Fosinopril: This drug contains a phosphinate group that binds to the active site of ACE. 
Liver esterase is cleaved and, with this prodrug that is converted to fosinopril, more potent 
than captopril and less potent than enalaprilat. 
In pathological conditions such as hypertension, ACE inhibitors promote the reduction of 
systemic vascular resistance and various hypertensive states. This effect, as mentioned 
above arises from the action of reducing the production of angiotensin II, thereby reducing 
their pressor effects and vascular remodeling. But what must be understood is that 
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angiotensin II has several other effects not only of increased blood pressure. These effects 
range from increased expression of proto-oncogene to the inflammation process. In the last 
decade studies have shown a strong relationship that RAS blockers possess anti 
atherosclerosis not only by regulating blood pressure, but also for its anti-inflammatory and 
antioxidant (Montecucco et al, 2009 and Schmieder et al, 2007 ). In this sense it is observed 
that studies that angiotensin II also acts on the expression of adhesion molecules such as 
intracellular adhesion molecule (ICAM), vasocelular adhesion molecule (VCAM), the P-
selectin molecules expressed in the inflammatory process, and promote the expression of 
chemokines, growth factors and cytokines. Our study showed that angiotensin promotes the 
activation of certain stellate cells, which promote active since the deposition of collagen 
formation and fibrosis. So regardless of the mechanisms involved ACE inhibitors have 
broad clinical utility as antihypertensive agents, but also has a great potential for the 
therapy of other vascular disorders, and it is observed in experimental models. 
Similarly antagonists of angiotensin II receptor act in lowering blood pressure, but unlike 
the effects of ACE inhibitors are not from inhibition of angiotensin II formation, but 
inhibition of its effects by antagonism of this peptide . This class of drugs bind to the AT1 
receptor with high affinity and, in general, are around 10,000 times more selective for this 
receptor than for the AT2. The pharmacology of these antagonists is well described in the 
literature. Goldman and Gilman shows that studies in vitro and in vivo of these drugs block 
the majority of the biological effects of angiotensin II such as contraction of vascular smooth 
muscle, fast pressor responses, slow pressor responses, thirst, release of vasopressin, 
aldosterone secretion , release of catecholamines by the adrenal glands, increased 
noradrenergic neurotransmission, increased sympathetic tone, impaired renal function, 
cellular hypertrophy and hyperplasia, and inhibit the activation of pancreatic stellate cells, 
protecting from injuries such as acute pancreatitis, the latter effect was observed by Silva, 
RB. et al, 2010. Drugs that make up this group are: candesartan, eprosartan, ibesartan, losartan, 
olmesartan, telmisartan and valsartan. 
Given this overview of the RAS and its relation to inflammation, we can observe that the 
drugs used to treat hypertension are consistent with the possible protective effects of a serial 
of inflammatory disorders. However the application of these to treat acute problems like 
apancreatite, for example, is not observed, but promising results from several studies, show 
that these drugs may be important in the treatment of various inflammatory disorders, is 
atherosclerosis, ischemia , or even pancreatitis. We observed in our work that pancreatic 
stellate cells respond to the action of angiotensin II (Figure 3 and 4) and in addition, we 
observed that these respond directly, because these cells have receptors for angiotensin II 
AT1 as illustrating the existence of even a Local RAS, regulating the vasculature of the tissue 
in question. Because of this, these drugs as mentioned above, could be a viable alternative to 
treat these other disorders. 
In our study we observed that the strength pancreatic stellate cells in collagen production 
are involved during acute pancreatitis and possibly that these can become active cells 
through the action of angiotensin II produced by rennin-angiotensin system. However it has 
been suggested an increasingly close relationship between the RAS and the inflammatory 
process in this sense these studies indicate a relationship of therapy used to treat 
hypertension is also feasible in other disorders such as inflammatory problems. 
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Fig. 3. Comparison of the number of pancreatic stellate cells marked for alpha-smooth 
muscle actin (ǂ-SMA) and fibrillary acidic protein glial (GFAP), and the percentage of points 
scored by used. The (PS), between the pancreas of control rats treated with lisinopril and 
losartan. The bars represent the mean ± SD. * P <0.001, compared to the treaties. 
 
Fig. 4. Slides stained by hematoxylin and eosin (A) to inflammatory analysis have showed 
more neutrophylic inflammatory infiltrate in sample of control group measured in [purple]. 
Moreover slides stained by Sirius red (B) have showed more collagen deposit in the animals 
of control group too showed in [eosinofilic]. In the group treated (C) and stained by 
immunohistochemical staining method (GFAP or ǂ-SMA) have less PSCs activated marked 
in [blue] compared with animals control (D and E) which have more PSCs activated 
measured in [red] (p<0.05) 
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